SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...
HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-CO...
* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characteri...
WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leadi...
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* The Company demonstrated a deep commitment to achieving ESG success in partnership with global ...
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Mi...
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* Named Top-Rated for fourth consecutive year * Committed to generating long-term value for all ...
- First manufacturing run successful for MFG7 facility at the Ireland site - Largest manufacturing...
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy ...
SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities i...
* Identified as a global sustainability leader by S&P Global * Committed to generating long-term...
* Ranked in top 1% of the over 100,000 companies evaluated * Recognized for outstanding performa...
* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug subst...
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Cont...
* WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibilit...